APO Research
Talk to an analyst

APO RESEARCH · REPORT

Manufacturing Execution Systems for Pharma and Biotech

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Manufacturing Execution Systems for Pharma and Biotech Market Outlook and Growth Opportunities 2026

1 January 2026207 pages

Choose your research edition.

Industry ResearchManufacturing Execution Systems for Pharma and Biotech Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Manufacturing Execution Systems for Pharma and Biotech Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Manufacturing Execution Systems for Pharma and Biotech Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Manufacturing Execution Systems for Pharma and Biotech Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Manufacturing Execution Systems for Pharma and Biotech Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Manufacturing Execution Systems for Pharma and Biotech market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Manufacturing Execution Systems for Pharma and Biotech is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Manufacturing Execution Systems for Pharma and Biotech is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Manufacturing Execution Systems for Pharma and Biotech is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Manufacturing Execution Systems for Pharma and Biotech market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Manufacturing Execution Systems for Pharma and Biotech market include Lonza, Vimachem, Korber, MasterControl, POMS Corporation, AspenTech, GE Vernova, 凯睿德 and Dassault Systemes, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Manufacturing Execution Systems for Pharma and Biotech market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Manufacturing Execution Systems for Pharma and Biotech and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Manufacturing Execution Systems for Pharma and Biotech revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Manufacturing Execution Systems for Pharma and Biotech market.

Manufacturing Execution Systems for Pharma and Biotech Segment by Company

Lonza

Vimachem

Korber

MasterControl

POMS Corporation

AspenTech

GE Vernova

凯睿德

Dassault Systemes

IBM

Rockwell Automation

ABB

Accevo Systems

AmpleLogic

Siemens Software

NNIT

Metronik

Tulip

Manufacturing Execution Systems for Pharma and Biotech Segment by Type

Cloud-based

On-premises

Manufacturing Execution Systems for Pharma and Biotech Segment by Application

Large Enterprises

SMEs

Manufacturing Execution Systems for Pharma and Biotech Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Manufacturing Execution Systems for Pharma and Biotech status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Manufacturing Execution Systems for Pharma and Biotech key companies, revenue, market share, and recent developments.

3. To split the Manufacturing Execution Systems for Pharma and Biotech breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Manufacturing Execution Systems for Pharma and Biotech market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Manufacturing Execution Systems for Pharma and Biotech significant trends, drivers, influence factors in global and regions.

6. To analyze Manufacturing Execution Systems for Pharma and Biotech competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Manufacturing Execution Systems for Pharma and Biotech market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Manufacturing Execution Systems for Pharma and Biotech and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Manufacturing Execution Systems for Pharma and Biotech.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Manufacturing Execution Systems for Pharma and Biotech industry.

Chapter 3: Detailed analysis of Manufacturing Execution Systems for Pharma and Biotech company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Manufacturing Execution Systems for Pharma and Biotech in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Manufacturing Execution Systems for Pharma and Biotech in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Manufacturing Execution Systems for Pharma and Biotech Industry Trends Table 2. Manufacturing Execution Systems for Pharma and Biotech Industry Drivers Table 3. Manufacturing Execution Systems for Pharma and Biotech Industry Opportunities and Challenges Table 4. Manufacturing Execution Systems for Pharma and Biotech Industry Restraints Table 5. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Company (2021-2026) Table 7. Global Manufacturing Execution Systems for Pharma and Biotech Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Manufacturing Execution Systems for Pharma and Biotech Key Company Manufacturing Base & Headquarters Table 9. Global Manufacturing Execution Systems for Pharma and Biotech Company, Product Type & Application Table 10. Global Manufacturing Execution Systems for Pharma and Biotech Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Manufacturing Execution Systems for Pharma and Biotech by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cloud-based Table 15. Significant Companies of On-premises Table 16. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type (2021-2026) Table 20. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Large Enterprises Table 22. Significant Companies of SMEs Table 23. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application (2021-2026) Table 27. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application (2027-2032) Table 28. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Region (2021-2026) Table 31. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Region (2027-2032) Table 33. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Market Share by Country (2021-2026) Table 36. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Market Share by Country (2027-2032) Table 38. Lonza Company Information Table 39. Lonza Business Overview Table 40. Lonza Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Lonza Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 42. Lonza Recent Development Table 43. Vimachem Company Information Table 44. Vimachem Business Overview Table 45. Vimachem Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Vimachem Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 47. Vimachem Recent Development Table 48. Korber Company Information Table 49. Korber Business Overview Table 50. Korber Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Korber Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 52. Korber Recent Development Table 53. MasterControl Company Information Table 54. MasterControl Business Overview Table 55. MasterControl Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. MasterControl Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 57. MasterControl Recent Development Table 58. POMS Corporation Company Information Table 59. POMS Corporation Business Overview Table 60. POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 62. POMS Corporation Recent Development Table 63. AspenTech Company Information Table 64. AspenTech Business Overview Table 65. AspenTech Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AspenTech Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 67. AspenTech Recent Development Table 68. GE Vernova Company Information Table 69. GE Vernova Business Overview Table 70. GE Vernova Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. GE Vernova Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 72. GE Vernova Recent Development Table 73. 凯睿德 Company Information Table 74. 凯睿德 Business Overview Table 75. 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 77. 凯睿德 Recent Development Table 78. Dassault Systemes Company Information Table 79. Dassault Systemes Business Overview Table 80. Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 82. Dassault Systemes Recent Development Table 83. IBM Company Information Table 84. IBM Business Overview Table 85. IBM Manufacturing Execution Systems for Pharma and Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. IBM Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 87. IBM Recent Development Table 88. Rockwell Automation Company Information Table 89. Rockwell Automation Business Overview Table 90. Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 92. Rockwell Automation Recent Development Table 93. ABB Company Information Table 94. ABB Business Overview Table 95. ABB Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. ABB Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 97. ABB Recent Development Table 98. Accevo Systems Company Information Table 99. Accevo Systems Business Overview Table 100. Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 102. Accevo Systems Recent Development Table 103. AmpleLogic Company Information Table 104. AmpleLogic Business Overview Table 105. AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 107. AmpleLogic Recent Development Table 108. Siemens Software Company Information Table 109. Siemens Software Business Overview Table 110. Siemens Software Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Siemens Software Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 112. Siemens Software Recent Development Table 113. NNIT Company Information Table 114. NNIT Business Overview Table 115. NNIT Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. NNIT Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 117. NNIT Recent Development Table 118. Metronik Company Information Table 119. Metronik Business Overview Table 120. Metronik Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Metronik Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 122. Metronik Recent Development Table 123. Tulip Company Information Table 124. Tulip Business Overview Table 125. Tulip Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Tulip Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 127. Tulip Recent Development Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Manufacturing Execution Systems for Pharma and Biotech Product Image Figure 2. Global Manufacturing Execution Systems for Pharma and Biotech Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032) & (US$ Million) Figure 4. Global Manufacturing Execution Systems for Pharma and Biotech Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cloud-based Image Figure 8. On-premises Image Figure 9. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type (2021-2032) Figure 12. Large Enterprises Image Figure 13. SMEs Image Figure 14. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application (2021-2032) Figure 17. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032) & (US$ Million) Figure 20. North America Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032) & (US$ Million) Figure 26. South America Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Cloud-based
  • On-premises
Applications
  • Large Enterprises
  • SMEs
Companies covered
  • Lonza
  • Vimachem
  • Korber
  • MasterControl
  • POMS Corporation
  • AspenTech
  • GE Vernova
  • 凯睿德
  • Dassault Systemes
  • IBM
  • Rockwell Automation
  • ABB
  • Accevo Systems
  • AmpleLogic
  • Siemens Software
  • NNIT
  • Metronik
  • Tulip

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Manufacturing Execution Systems for Pharma and Biotech Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Manufacturing Execution Systems for Pharma and Biotech Market Dynamics
  1. 2.1 Manufacturing Execution Systems for Pharma and Biotech Industry Trends
  2. 2.2 Manufacturing Execution Systems for Pharma and Biotech Industry Drivers
  3. 2.3 Manufacturing Execution Systems for Pharma and Biotech Industry Opportunities and Challenges
  4. 2.4 Manufacturing Execution Systems for Pharma and Biotech Industry Restraints
3 Manufacturing Execution Systems for Pharma and Biotech Market by Company
  1. 3.1 Global Manufacturing Execution Systems for Pharma and Biotech Company Revenue Ranking in 2025
  2. 3.2 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Company (2021-2026)
  3. 3.3 Global Manufacturing Execution Systems for Pharma and Biotech Company Ranking (2024-2026)
  4. 3.4 Global Manufacturing Execution Systems for Pharma and Biotech Company Manufacturing Base and Headquarters
  5. 3.5 Global Manufacturing Execution Systems for Pharma and Biotech Company Product Type and Application
  6. 3.6 Global Manufacturing Execution Systems for Pharma and Biotech Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Manufacturing Execution Systems for Pharma and Biotech Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Manufacturing Execution Systems for Pharma and Biotech Market by Type
  1. 4.1 Manufacturing Execution Systems for Pharma and Biotech Type Introduction
  2. 4.1.1 Cloud-based
  3. 4.1.2 On-premises
  4. 4.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type
  5. 4.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Type (2021-2032)
  7. 4.2.3 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type (2021-2032)
5 Manufacturing Execution Systems for Pharma and Biotech Market by Application
  1. 5.1 Manufacturing Execution Systems for Pharma and Biotech Application Introduction
  2. 5.1.1 Large Enterprises
  3. 5.1.2 SMEs
  4. 5.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application
  5. 5.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Application (2021-2032)
  7. 5.2.3 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application (2021-2032)
6 Manufacturing Execution Systems for Pharma and Biotech Regional Value Analysis
  1. 6.1 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Region (2021-2032)
  3. 6.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Region: 2021-2026
  4. 6.2.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032)
  7. 6.3.2 North America Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032)
  10. 6.4.2 Europe Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032)
  16. 6.6.2 South America Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Country, 2025 VS 2032
7 Manufacturing Execution Systems for Pharma and Biotech Country-level Value Analysis
  1. 7.1 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country (2021-2032)
  3. 7.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country (2021-2026)
  4. 7.2.2 Global Manufacturing Execution Systems for Pharma and Biotech Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Manufacturing Execution Systems for Pharma and Biotech Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Manufacturing Execution Systems for Pharma and Biotech Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Vimachem
  8. 8.2.1 Vimachem Company Information
  9. 8.2.2 Vimachem Business Overview
  10. 8.2.3 Vimachem Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Vimachem Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  12. 8.2.5 Vimachem Recent Developments
  13. 8.3 Korber
  14. 8.3.1 Korber Company Information
  15. 8.3.2 Korber Business Overview
  16. 8.3.3 Korber Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Korber Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  18. 8.3.5 Korber Recent Developments
  19. 8.4 MasterControl
  20. 8.4.1 MasterControl Company Information
  21. 8.4.2 MasterControl Business Overview
  22. 8.4.3 MasterControl Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MasterControl Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  24. 8.4.5 MasterControl Recent Developments
  25. 8.5 POMS Corporation
  26. 8.5.1 POMS Corporation Company Information
  27. 8.5.2 POMS Corporation Business Overview
  28. 8.5.3 POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  29. 8.5.4 POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  30. 8.5.5 POMS Corporation Recent Developments
  31. 8.6 AspenTech
  32. 8.6.1 AspenTech Company Information
  33. 8.6.2 AspenTech Business Overview
  34. 8.6.3 AspenTech Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AspenTech Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  36. 8.6.5 AspenTech Recent Developments
  37. 8.7 GE Vernova
  38. 8.7.1 GE Vernova Company Information
  39. 8.7.2 GE Vernova Business Overview
  40. 8.7.3 GE Vernova Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GE Vernova Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  42. 8.7.5 GE Vernova Recent Developments
  43. 8.8 凯睿德
  44. 8.8.1 凯睿德 Company Information
  45. 8.8.2 凯睿德 Business Overview
  46. 8.8.3 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  47. 8.8.4 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  48. 8.8.5 凯睿德 Recent Developments
  49. 8.9 Dassault Systemes
  50. 8.9.1 Dassault Systemes Company Information
  51. 8.9.2 Dassault Systemes Business Overview
  52. 8.9.3 Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  54. 8.9.5 Dassault Systemes Recent Developments
  55. 8.10 IBM
  56. 8.10.1 IBM Company Information
  57. 8.10.2 IBM Business Overview
  58. 8.10.3 IBM Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  59. 8.10.4 IBM Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  60. 8.10.5 IBM Recent Developments
  61. 8.11 Rockwell Automation
  62. 8.11.1 Rockwell Automation Company Information
  63. 8.11.2 Rockwell Automation Business Overview
  64. 8.11.3 Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  66. 8.11.5 Rockwell Automation Recent Developments
  67. 8.12 ABB
  68. 8.12.1 ABB Company Information
  69. 8.12.2 ABB Business Overview
  70. 8.12.3 ABB Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ABB Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  72. 8.12.5 ABB Recent Developments
  73. 8.13 Accevo Systems
  74. 8.13.1 Accevo Systems Company Information
  75. 8.13.2 Accevo Systems Business Overview
  76. 8.13.3 Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  78. 8.13.5 Accevo Systems Recent Developments
  79. 8.14 AmpleLogic
  80. 8.14.1 AmpleLogic Company Information
  81. 8.14.2 AmpleLogic Business Overview
  82. 8.14.3 AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  84. 8.14.5 AmpleLogic Recent Developments
  85. 8.15 Siemens Software
  86. 8.15.1 Siemens Software Company Information
  87. 8.15.2 Siemens Software Business Overview
  88. 8.15.3 Siemens Software Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Siemens Software Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  90. 8.15.5 Siemens Software Recent Developments
  91. 8.16 NNIT
  92. 8.16.1 NNIT Company Information
  93. 8.16.2 NNIT Business Overview
  94. 8.16.3 NNIT Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  95. 8.16.4 NNIT Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  96. 8.16.5 NNIT Recent Developments
  97. 8.17 Metronik
  98. 8.17.1 Metronik Company Information
  99. 8.17.2 Metronik Business Overview
  100. 8.17.3 Metronik Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Metronik Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  102. 8.17.5 Metronik Recent Developments
  103. 8.18 Tulip
  104. 8.18.1 Tulip Company Information
  105. 8.18.2 Tulip Business Overview
  106. 8.18.3 Tulip Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Tulip Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  108. 8.18.5 Tulip Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst